Microarray-Based Gene Expression Studies in Ovarian Cancer

Jemal A. , Siegel R. , Xu J. . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5): 277–300.

Harries M. , Kaye S.B. . Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs. 2001; 10(9): 1715–1724.

Kulesh D.A. , Clive D.R. , Zarlenga D.S. . Identification of interferon-modulated proliferation-related cDNA sequences. Proc Natl Acad Sci U S A. 1987; 84(23): 8453–8457.

Lashkari D.A. , DeRisi J.L. , McCusker J.H. . Yeast microarrays for genome wide parallel genetic and gene expression analysis. Proc Natl Acad Sci U S A. 1997; 94(24): 13057–13062.

Gilks C.B. , Vanderhyden B.C. , Zhu S. . Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol. 2005; 96(3): 684–694.

Schaner M.E. , Ross D.T. , Ciaravino G. . Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003; 14(11): 4376–4386.

Bonome T. , Lee J.Y. , Park D.C. . Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005; 65(22): 10602–10612.

Mok S.C. , Chao J. , Skates S. . Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst. 2001; 93(19): 1458–1464.

Spentzos D. , Levine D.A. , Kolia S. . Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005; 23(31): 7911–7918.

Spentzos D. , Levine D.A. , Ramoni M.F. . Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004; 22(23): 4700–4710.

Dufva M. . Fabrication of DNA microarray. Methods Mol Biol. 2009; 529: 63–79.

Pease A.C. , Solas D. , Sullivan E.J. . Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A. 1994; 91(11): 5022–5026.

Kuhn K. , Baker S.C. , Chudin E. . A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res. 2004; 14(11): 2347–2356.

Hoshida Y. , Villanueva A. , Kobayashi M. . Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359(19): 1995–2004.

Chien J. , Fan J.B. , Bell D.A. . Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol. 2009; 114(1): 3–11.

Brazma A. , Hingamp P. , Quackenbush J. . Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001; 29(4): 365–371.

Shi L. , Reid L.H. , Jones W.D. . The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006; 24(9): 1151–1161.

Golub T.R. , Slonim D.K. , Tamayo P. . Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286(5439): 531–537.

Giordano T.J. , Shedden K.A. , Schwartz D.R. . Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol. 2001; 159(4): 1231–1238.

Schwartz D.R. , Kardia S.L. , Shedden K.A. . Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002; 62(16): 4722–4729.

Zorn K.K. , Bonome T. , Gangi L. . Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005; 11(18): 6422–6430.

Motzer R.J. , Agarwal N. , Beard C. . NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009; 7(6): 618–630.

Rauh-Hain J.A. , Penson R.T. . Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer. 2008; 18(5): 934–936.

Singer G. , Kurman R.J. , Chang H.W. . Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002; 160(4): 1223–1228.

Anglesio M.S. , Arnold J.M. , George J. . Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RASMAPK in ovarian serous low malignant potential tumors. Mol Cancer Res. 2008; 6(11): 1678–1690.

Tothill R.W. , Tinker A.V. , George J. . Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14(16): 5198–5208.

Kim J.H. , Skates S.J. , Uede T. . Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002; 287(13): 1671–1679.

Wong K.K. , Cheng R.S. , Mok S.C. . Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques. 2001; 30(3): 670–675.

Meinhold-Heerlein I. , Bauerschlag D. , Zhou Y. . An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res. 2007; 13(2 Pt 1): 458–466.

Kim J.H. , Herlyn D. , Wong K.K. . Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res. 2003; 9(13): 4782–4791.

Shvartsman H.S. , Lu K.H. , Lee J. . Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003; 90(1): 44–50.

Huddleston H.G. , Wong K.K. , Welch W.R. . Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol. 2005; 96(1): 77–83.

Mor G. , Visintin I. , Lai Y. . Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(21): 7677–7682.

Berchuck A. , Iversen E.S. , Luo J. . Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res. 2009; 15(7): 2448–2455.

Hartmann L.C. , Lu K.H. , Linette G.P. . Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005; 11(6): 2149–2155.

Lancaster J.M. , Dressman H.K. , Whitaker R.S. . Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig. 2004; 11(1): 51–59.

Berchuck A. , Iversen E.S. , Lancaster J.M. . Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005; 11(10): 3686–3696.

Moss C. , Kaye S.B. . Ovarian cancer: progress and continuing controversies in management. Eur J Cancer. 2002; 38(13): 1701–1707.

von Georgi R. , Franke F.E. , Munstedt K. . Influence of surgery and postoperative therapy and tumor characteristics on patient prognosis in advanced ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol. 2003; 111(2): 189–196.

Helleman J. , Jansen M.P. , Span P.N. . Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 2006; 118(8): 1963–1971.

Dressman H.K. , Berchuck A. , Chan G. . An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007; 25(5): 517–525.

Potti A. , Dressman H.K. , Bild A. . Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006; 12(11): 1294–1300.

Jazaeri A.A. , Awtrey C.S. , Chandramouli G.V. . Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005; 11(17): 6300–6310.

Selvanayagam Z.E. , Cheung T.H. , Wei N. . Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet. 2004; 154(1): 63–66.

Roberts D. , Schick J. , Conway S. . Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer. 2005; 92(6): 1149–1158.